Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Vilon

Lys-Glu Immune Dipeptide (Khavinson)

Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.

Vilon (Lys-Glu) rests on animal and in-vitro work from Khavinson and Anisimov, including a CBA-mouse study associating the dipeptide with reduced spontaneous tumor incidence and longer lifespan (Dokl Biol Sci 2000, PMID 10944717), plus unreplicated Russian clinical reports collected in the Institute of Bioregulation and Gerontology reviews. No Western randomized controlled trial supports any human immune or geroprotective claim, so the honest grade is 1 (animal and traditional-clinical only), not the current 2.

FDA
Not approved by the FDA for any indication. Sold in the United States and elsewhere only as a research chemical for laboratory use, labeled not for human consumption.
WADA
Not listed by name on the WADA Prohibited List. No anti-doping approval is implied; status may fall under broader catch-all categories and should not be read as permission for human use.

Reference only. Not medical advice.

What can go wrong

Evidence is preclinical plus unreplicated single-center Russian clinical reports, with no Western RCTs and an unapproved research-chemical supply of uncertain purity.

Talk to a clinician before taking this. The Atlas can tell you what has been studied about Vilon. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

A Khavinson dipeptide bioregulator with Russian data on immune restoration and gene expression in aging. One of the shortest peptides in the bioregulator system.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Immune restoration (Russian data)
  • Longevity protocol

How it is supposed to work

Vilon is a synthetic dipeptide (lysine and glutamic acid), one of the most-studied of the short bioregulator peptides, directed at the immune system. Research in the tradition focuses on restoring T-cell activity and cytokine patterns in aged animals toward younger profiles. Its DNA-level mechanism is plausible in principle but unproven for this peptide in humans.

Vilon is a synthetic dipeptide, lysine and glutamic acid, one of the second-generation defined-sequence bioregulators and a synthetic relative of the thymus extract Thymalin. Its extreme simplicity, two residues, is part of why the family’s direct gene-regulation theory is so striking and so contested.

Type
Synthetic dipeptide
Sequence
Lys-Glu
Target
Immune and thymus
Generation
Second (defined)
Evidence
Animal, from one group
Western RCT
None

A Two-Amino-Acid Immune Bioregulator With Animal-Lifespan Claims

Vilon is interesting mostly for what it claims and how thin the independent confirmation is. The headline result from the originating program is that lifelong intermittent dosing extended maximum lifespan in animals, with restored immune markers in aged subjects, which is exactly the kind of finding that would be transformative if reproduced. It is also the kind of finding that demands independent replication before it means anything, and that replication does not exist. As a two-amino-acid molecule it embodies the family’s central hypothesis, direct nuclear gene regulation, in its most extreme and least conventional form. The honest read is that Vilon is a provocative claim resting entirely on one research lineage, not an established longevity intervention.

Safety in detail

The human safety profile is not established from controlled Western trials. Material sold as Vilon is unregulated research chemical, so identity, purity, and sterility are not guaranteed, and reported benefits are associated with animal and Russian-only data rather than confirmed in humans.

  • Reported safety in decades of Russian clinical use is described as clean, with few serious adverse events, but that record comes largely from within the same research tradition that developed the peptides and has not been independently verified in Western trials.
  • Long-term safety in rigorous, controlled human studies is essentially uncharacterized outside that tradition.
  • Most material sold internationally is gray-market or supplement-grade, so unverified identity, dose and purity are the dominant practical risks.
  • Not FDA-approved for any use; claims of disease treatment are not supported by Western regulatory review.

Children and teenagers

Vilon has no validated pediatric use and is an unapproved injected peptide. There is no appropriate pediatric use.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Vilon reaches users through the international bioregulator gray market and longevity vendors selling the Khavinson line. There is no approved product. Its appeal rests on a dramatic but unconfirmed animal-lifespan claim.

How we got here

Vilon began as the immune-active fraction of Thymalin, a thymus-tissue extract studied at the St. Petersburg Institute of Bioregulation and Gerontology, and was reduced by Vladimir Khavinson and colleagues to the defined synthetic dipeptide Lys-Glu (KE), the shortest member of the Khavinson short-peptide bioregulator system. Within that system it sits in the synthetic Cytogen line, paralleling the natural Cytomax and Cytamin thymus preparations and the Vladonix immune complex sold in Russia. Outside Russia it circulates as an unapproved research chemical under the name Vilon and its sequence names, and it is often confused with the pineal peptide Epithalon because both are Khavinson bioregulators, which is how it landed in this library under the mismatched legacy id `epithalon-b`.

Vilon was developed as a defined-sequence dipeptide at the St. Petersburg institute, the synthetic immune counterpart to the older Thymalin extract, and became a centerpiece of the program’s animal-lifespan research.

The numbers behind the grade

Type
Dipeptide (Lys-Glu)
Target
Immune system
Russia
Bioregulator line
FDA
Not approved
Evidence
Single-tradition
Western RCTs
None

The people taking it

One of the most-studied dipeptide bioregulators, well known in longevity circles for its claimed immune and lifespan effects.

Vilon’s users are longevity enthusiasts drawn to its lifespan claim, the bioregulator-protocol community, and immune-focused biohackers.

Used as an immune-restoration and longevity bioregulator within Russian-tradition protocols; rodent lifespan claims are not independently confirmed in humans.

Set against the alternatives

Vilon is the synthetic immune dipeptide counterpart to the natural thymus extract Thymalin, and a sibling of the other immune dipeptide Thymogen. Against a Western thymic peptide like thymosin alpha-1, with its multi-country approval and broader data, Vilon is the same organ system approached on a far narrower and unreplicated evidence base. Across the family it shares Epithalon’s longevity framing while targeting immunity rather than the pineal gland.

What we do not know

  • Whether independent, Western randomized trials confirm any of the claimed clinical effects.
  • Whether the proposed DNA-binding, gene-regulating mechanism actually operates in human tissue at the doses used.
  • Why, after forty years and hundreds of papers, replication outside the originating institute remains so limited.
  • Whether results from complex tissue extracts (Cytomaxes) translate to the defined synthetic peptides (Cytogens) sold alongside them.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Available internationally as oral or injectable bioregulator supplements (Cytogen and Cytomax lines) and as research-use-only peptide vials, with legal status varying by country. None is an FDA-approved medicine, so there is no regulated US prescription route; the honest course is to treat the claims with caution and consult a clinician.

Material reaches international buyers two ways: as branded Cytogen (synthetic) or Cytomax (animal-tissue extract) supplements produced in Russia, and as research-use-only vials, much of it synthesized in China. Neither route guarantees the identity or potency the label claims, so an independent certificate of analysis is the only real check and is uncommon.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Vilon.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Supply chain. We have not mapped where it is made.
  • What could change. No forward-looking summary yet.

Sources

The studies that matter

  • Khavinson group studies1990s-2010s

    Reported immune restoration and, in rodent studies, lifespan-extension signals; among the most-cited cytogen dipeptides.

  • Independent replicationlimited

    A little independent interest exists in short immune-peptides, but rigorous independent Western trials of Vilon are lacking.